Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class.
This article published in the New England Journal of Medicine
N Engl J Med 2019; 381:1-4 DOI: 10.1056/NEJMp1903305
discusses Esketamine approval for treatment-resistant depression.
The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset of effect against its abuse potential, which led to a Risk Evaluation and Mitigation Strategy.